Financial Trends -- 5/10

TREX is in a cyclical trough with the R&R market declining for a third consecutive year. Revenue is essentially flat over 5 years ($1,197M in FY2021 vs $1,174M in FY2025). Margins compressed ~300bps in FY2025 due to Arkansas facility startup costs and lower utilization. Diluted EPS of $1.78 in FY2025 is below the FY2021 level of $1.80 -- five years of no EPS growth. However, FCF turned positive in FY2025 after a capex-heavy FY2024, sell-through (mid-single digits) is outpacing reported revenue due to channel destocking, and the share count is declining ~2% annually. The trough is cyclical, not structural. Weight: 25%
FY2025 Revenue
$1,174M
+2.0% YoY | Still below FY2021 peak
FY2025 Diluted EPS
$1.78
Below FY2021 $1.80 | No 5yr growth
FY2025 EBITDA Margin
27.3%
-400bps YoY | Arkansas startup drag
FY2025 FCF
$125M
Positive again | 10.6% FCF margin
Revenue Trajectory (USD M, Quarterly)
Highly seasonal business with choppy YoY growth. Revenue oscillated between destocking-driven declines and normalization over the last 12 quarters. Q1-Q2 are structurally the strongest quarters (spring deck-building season), while Q4 is consistently the weakest. FY2025 grew only +2.0% following +5.2% in FY2024 -- the third consecutive year below the FY2021 peak of $1,197M. Sell-through growth (mid-single digits per management) is better than reported revenue because of channel inventory normalization. Consensus expects ~$1.25B for FY2026E (~+6%).
MetricQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue ($M)$238.7M$356.5M$303.8M$195.7M$373.6M$376.5M$233.7M$167.6M$340.0M$387.8M$285.4M$161.1M
YoY Growth-29.7%-7.8%61.2%1.9%56.5%5.6%-23.1%-14.4%-9.0%3.0%22.1%-3.9%
FY2021: $1,197M | FY2022: $1,106M (-7.6%) | FY2023: $1,095M (-1.0%) | FY2024: $1,151M (+5.2%) | FY2025: $1,174M (+2.0%). Data sourced from Daloopa.

Revenue YoY Growth Trend
Growth whipsawed between -30% and +61% on channel dynamics. The extreme swings reflect destocking/restocking cycles rather than underlying demand changes. Q3 2023 (+61.2%) and Q1 2024 (+56.5%) were easy-comp recoveries; Q3 2024 (-23.1%) and Q1 2025 (-9.0%) reflected channel destocking. The pattern has been stabilizing -- Q2 2025 (+3.0%) and Q3 2025 (+22.1%) showed improvement before Q4 2025 dipped slightly (-3.9%) on seasonal weakness.
Data sourced from Daloopa.

Annual Revenue (USD M)
MetricFY2021FY2022FY2023FY2024FY2025
Revenue ($M)$1,197M$1,106M$1,095M$1,151M$1,174M
YoY Growth-7.6%-1.0%5.2%2.0%
Revenue still below FY2021 peak after 4 years. FY2026E consensus ~$1.25B (+6%). Data sourced from Daloopa.

Margin Trends
Margins compressed ~300bps in FY2025 vs FY2024. Gross margin fell from 42.2% to 39.2%, driven by lower utilization at legacy plants as the new Arkansas facility ramps and higher raw material costs. Q4 seasonal weakness is structural -- low-volume quarter with fixed cost underabsorption (Q4 2025 gross margin just 30.2%). EBITDA margin declined from 31.3% to 27.3% (-400bps), with Q4 2025 hitting just 12.7%. EBITDA declined from $376.6M to $320.9M (-14.8%). The margin drag should ease as Arkansas ramps and the railing product mix transitions.
MetricFY2021FY2022FY2023FY2024FY2025
Gross Margin38.5%36.5%41.3%42.2%39.2%
EBITDA Margin26.0%26.3%29.8%31.3%27.3%
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Gross Margin45.4%44.7%39.9%32.7%40.5%40.8%40.5%30.2%
YoY Change (pp)5.8%0.8%-3.2%-2.6%-4.9%-3.9%0.6%-2.5%
GM compressed by Arkansas startup costs and lower utilization. Q4 structural weakness from fixed cost underabsorption. Data sourced from Daloopa.

EBITDA Trajectory (USD M, Quarterly)
EBITDA declined -14.8% YoY from $376.6M to $320.9M. The decline is attributable to Arkansas facility startup costs, lower utilization, and the railing product mix transition. Q4 2025 EBITDA of just $20.4M (12.7% margin) reflects severe seasonal underabsorption. Q1-Q2 are structurally the best quarters for EBITDA given spring building season volumes. The H1 2025 vs H1 2024 comparison shows EBITDA stabilizing ($214M vs $264M).
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
EBITDA ($M)$133.2M$130.4M$67.9M$45.1M$95.9M$118.2M$86.4M$20.4M
EBITDA Margin35.6%34.6%29.1%26.9%28.2%30.5%30.3%12.7%
FY2024 EBITDA: $376.6M (31.3% margin). FY2025 EBITDA: $320.9M (27.3% margin). -14.8% YoY. Data sourced from Daloopa.

EPS Trajectory (Annual)
Five years of no EPS growth. Diluted EPS of $1.78 in FY2025 is below FY2021 ($1.80) and the FY2023 peak of $1.89. Adjusted diluted EPS of $1.88 is similarly flat. Despite a -9.7% reduction in share count over 4 years (115.1M to 103.9M), EPS has not grown, indicating the underlying earnings power has deteriorated. Consensus expects recovery to ~$2.05 in FY2026E and ~$2.35 in FY2027E as margins normalize post-Arkansas ramp and the R&R cycle turns.
MetricFY2021FY2022FY2023FY2025
Diluted EPS$1.8$1.6$1.9$1.8
Adj. Diluted EPS$2.1$1.8$1.9$1.9
FY2024 EPS not reported in source. FY2026E ~$2.05 | FY2027E ~$2.35 (consensus approximate). Data sourced from Daloopa.

Consensus Estimates vs. Actuals
Metric FY2025A FY2026E FY2027E
Revenue $1,174M ~$1,250M (+6%) ~$1,350M (+8%)
Diluted EPS $1.78 ~$2.05 (+15%) ~$2.35 (+15%)
EBITDA Margin 27.3% ~29-30% (recovering) ~31% (normalizing)
FCF $125M ~$200M+ (lower capex) ~$250M+
Consensus expects cyclical recovery, not a re-acceleration. Street expects mid-single-digit revenue growth as R&R market stabilizes and wood-to-composite conversion continues. EPS recovery to ~$2.05-$2.35 is predicated on margin normalization as Arkansas facility startup costs subside and utilization improves. FCF should benefit from significantly lower capex as the Arkansas build completes. The bull case requires the R&R cycle to turn -- the bear case is another year of flat-to-down.
Consensus estimates approximate. Recovery dependent on R&R cycle turn and Arkansas ramp completion. Data sourced from Daloopa.

Free Cash Flow (Annual, USD M)
FCF recovered to $125M in FY2025 after negative FY2024. FY2024 FCF was -$88M due to elevated capex (~$232M) for the Arkansas facility. FY2025 recovered to $125M (10.6% FCF margin) but remains well below FY2023 peak of $223M. Capex should normalize as the Arkansas build completes, which would unlock significantly more FCF. At normalized capex levels, TREX could generate $200M+ in FCF, supporting continued buyback activity.
MetricFY2022FY2023FY2024FY2025
FCF ($M)$47M$223M($88M)$125M
FCF Margin4.3%20.4%-7.6%10.6%
FY2024 FCF negative due to ~$232M capex for Arkansas facility. Capex normalizing in FY2026+. Data sourced from Daloopa.

Acceleration / Deceleration Analysis
Signal Detail Direction
Revenue Growth FY2025 +2.0% vs FY2024 +5.2%; annual growth decelerating but Q3 2025 spiked +22.1% Mixed
Gross Margin 42.2% to 39.2% (-300bps); Arkansas startup costs and lower utilization Compressing
EBITDA $376.6M to $320.9M (-14.8%); margin down -400bps to 27.3% Declining
Diluted EPS $1.78 in FY2025 vs $1.80 in FY2021; five years of zero EPS growth Flat/Declining
Free Cash Flow -$88M (FY2024) to +$125M (FY2025); positive inflection as capex normalizes Recovering
Share Count 115.1M to 103.9M (-9.7% over 4 years); ~2% annual reduction from buybacks Declining (positive)
Sell-Through vs. Reported Mid-single-digit sell-through outpacing +2% reported revenue; channel normalization ongoing Positive signal

Score Derivation
Component Assessment Score
Revenue growth and trajectory Flat over 5 years ($1,197M to $1,174M); +2% annual growth; choppy quarterly pattern 3.5
Gross margin quality Compressed -300bps from Arkansas startup; still decent at 39.2% but trending wrong direction 5.0
EBITDA / operating leverage -14.8% YoY decline; margin compressed -400bps; startup cost drag temporary 4.0
EPS trajectory $1.78 in FY2025 vs $1.80 in FY2021; zero growth over 5 years despite buybacks 3.0
FCF generation Recovered to $125M (+10.6% margin); negative in FY2024 was capex-driven, not operational 6.0
Capital return / dilution -9.7% share reduction over 4 years; ~2% annual buyback; no dilution 7.0
Penalty modifiers No penalties: FCF positive, no dilution, no debt growth faster than revenue 0
Final Score Cyclical trough, not structural; FCF positive, no dilution 5/10
Data sourced from Daloopa.